文献速递脊柱关节炎

生物制剂治疗启动时机与治疗线数对阿塞奇尤单抗在中轴型脊柱关节炎中留存率的影响:法国多中心回顾性FORSYA研究数据

Impact of the time of initiation and line of biologic therapy on the retention rate of secukinumab in axial spondyloarthritis (axSpA): data from the French multicentre retrospective FORSYA study.
PubMed 文献 · RMD Open · 2024-02-29

C2的1年留存率优于C1(64% vs 59%,HR=1.19,p=0.0297),多因素分析显示生物制剂治疗线数是两个队列中唯一预测1年留存率的因素,一线使用留存率更佳。

要点

  • C2队列1年留存率64%(61%-68%)优于C1队列59%(55%-62%),HR=1.19(1.02-1.39),p=0.0297。
  • 多因素分析显示,生物制剂治疗线数是两个队列中唯一预测1年留存率的因素。
  • 阿塞奇尤单抗作为一线生物制剂处方时留存率更佳。

核心结论

  • 阿塞奇尤单抗远离上市初期时留存率更优,归因于其在疾病更早期阶段使用,提示处方医生行为发生变化。
  • 作者认为结果强调了对常规诊疗治疗进行迭代评估的相关性。

研究设计与样本

  • 法国多中心回顾性研究,纳入中轴型脊柱关节炎患者。
  • 按阿塞奇尤单抗启动时间分为两个队列:C1为2016年8月16日至2018年8月31日,C2为2018年9月1日至2020年11月13日。
  • 共纳入50个中心的906例C1患者和758例C2患者。
  • 采用Kaplan-Meier法估计1年留存率,log-rank检验比较两队列留存曲线。
  • 采用单因素和多因素Cox模型回归分析预设因素(如疾病特征、阿塞奇尤单抗治疗线数和启动时间)与1年留存率的关系。

主要发现

  • C2的1年留存率为64%(61%-68%),C1为59%(55%-62%),C2较C1更优(HR=1.19(1.02-1.39);p=0.0297)。
  • 多因素分析中,生物制剂治疗线数是两个队列中唯一预测阿塞奇尤单抗1年留存率的因素,作为一线生物制剂处方时留存率更佳。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare the 1-year retention rate of secukinumab in axial spondyloarthritis (axSpA) and its predisposing factors with regard to its time of initiation (eg, right after or remotely from its launch). METHODS: Study design: Retrospective multicentre French study of patients with axSpA. Study periods: Two cohorts were evaluated regarding the time of initiation of secukinumab: cohort 1 (C1)-between 16 August 2016 and 31 August 2018-and cohort 2 (C2)-between 1 September 2018 and 13 November 2020. STATISTICAL ANALYSIS: The 1-year retention rate of secukinumab was estimated using the Kaplan-Meier method, and the log-rank test was used to compare the retention curves of the two cohorts. Preselected factors (eg, disease characterristics, line and time of secukinumab initiation) of secukinumab retention at 1 year were analysed by univariate and multivariate Cox model regression. RESULTS: In total, 906 patients in C1 and 758 in C2 from 50 centres were included in the analysis. The 1-year retention rate was better in C2 (64% (61%-68%)) vs C1 (59% (55%-62%)) (HR=1.19 (1.02-1.39); p=0.0297). In the multivariate analysis, the line of biologic therapy was the single predictive factor of the 1-year retention rate of secukinumab picked up in both cohorts, with a better retention rate when prescribed as first-line biologic therapy. CONCLUSION: The better secukinumab retention rate remotely from its launch is explained by its use at an earlier stage of the disease, suggesting a change in the behaviour of prescribing physicians. Our results emphasise the relevance of iterative evaluations of routine care treatments.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Dougados M, Lardy-Cléaud A, Desfleurs E, et al. Impact of the time of initiation and line of biologic therapy on the retention rate of secukinumab in axial spondyloarthritis (axSpA): data from the French multicentre retrospective FORSYA study. RMD Open. 2024. PMID: 38428974. doi:10.1136/rmdopen-2023-003942

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。